Package | us.nlm.vsac |
Resource Type | ValueSet |
Id | 2.16.840.1.113762.1.4.1178.43 |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1178.43/expansion |
URL | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43 |
Version | 20220716 |
Status | active |
Date | 2022-07-16T01:02:12-04:00 |
Name | SGLT2Ingredients |
Title | SGLT2 Ingredients |
Realm | us |
Authority | hl7 |
Purpose | (Clinical Focus: The purpose of this value set is to represent concepts for medications of sodium glucose co-transporter 2 (SGLT2) ingredients.),(Data Element Scope: This value set may use a model element related to Allergy/Intolerance.),(Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable sodium glucose co-transporter 2 (SGLT2) ingredients only.),(Exclusion Criteria: No exclusions.) |
No resources found
CodeSystem | |
rxnorm | RxNorm |
No narrative content found in resource
{ "resourceType": "ValueSet", "id": "2.16.840.1.113762.1.4.1178.43", "meta": { "versionId": "5", "lastUpdated": "2023-12-21T17:43:03.000-05:00", "profile": [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ] }, "extension": [ { "url": "http://hl7.org/fhir/StructureDefinition/valueset-author", "valueContactDetail": { "name": "AHA Author" } }, { "url": "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate", "valueDate": "2025-03-10" }, { "url": "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate", "valueDate": "2022-07-16" } ], "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43", "identifier": [ { "system": "urn:ietf:rfc:3986", "value": "urn:oid:2.16.840.1.113762.1.4.1178.43" } ], "version": "20220716", "name": "SGLT2Ingredients", "title": "SGLT2 Ingredients", "status": "active", "experimental": false, "date": "2022-07-16T01:02:12-04:00", "publisher": "AHA Steward", "jurisdiction": [ { "coding": [ { "system": "urn:iso:std:iso:3166", "code": "US" } ] } ], "purpose": "(Clinical Focus: The purpose of this value set is to represent concepts for medications of sodium glucose co-transporter 2 (SGLT2) ingredients.),(Data Element Scope: This value set may use a model element related to Allergy/Intolerance.),(Inclusion Criteria: Includes concepts that represent an allergy or intolerance for prescribable sodium glucose co-transporter 2 (SGLT2) ingredients only.),(Exclusion Criteria: No exclusions.)", "compose": { "include": [ { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "concept": [ { "code": "1373458", "display": "canagliflozin" }, { "code": "1488564", "display": "dapagliflozin" }, { "code": "1545653", "display": "empagliflozin" }, { "code": "1992672", "display": "ertugliflozin" } ] } ] }, "expansion": { "identifier": "urn:uuid:5c4f4503-ba0a-45f6-aaa2-c4ba28dfaaa3", "timestamp": "2025-05-23T19:08:06-04:00", "total": 4, "contains": [ { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1373458", "display": "canagliflozin" }, { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1488564", "display": "dapagliflozin" }, { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1545653", "display": "empagliflozin" }, { "system": "http://www.nlm.nih.gov/research/umls/rxnorm", "version": "05052025", "code": "1992672", "display": "ertugliflozin" } ] } }